Candesartan

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Candesartan

Examples of brand names: Atacand [DE]

ATC code: C09CA06

Main use (for orientation): Hypertension; heart failure

Documented research summary

No results in the drug-specific title search; cross-reference from the original telmisartan study: CBD/candesartan 5/5 µM in BV2 cells, NO reduction 68% versus 62% with CBD alone. No clinical effect or safety established.

Uncertainties and limitations

Original study found through a cross-reference from telmisartan research; no results in the drug-specific title search. Abstract and relevant full-text sections read.

Missing data do not establish safety. Research is limited by the documented sources, search terms, languages and accessibility.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0427

Type of result: Preclinical endpoint

Observation: The combination reduced NO by approximately 68%, CBD alone by 62%, candesartan alone by 40%; the combination value was similar to CBD alone.

Mechanism: Combined modulation of LPS-induced NO production in murine BV2 microglial cells; no pharmacokinetic evidence.

Study type: Original in vitro study

Context studied: CBD 5 µM and candesartan 5 µM; LPS 7 ng/ml; 24 hours; two independent experiments, n=8 measurements.

Clinical interpretation: Clinical significance unresolved

Limitations and uncertainties: Cell experiment, no blood-pressure, efficacy or human interaction data. A numerically larger value does not establish synergy here.

Original sources for this finding: An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release. [RMED38003444]

References and access status

[VD_LABEL_D0219] ATACAND (CANDESARTAN CILEXETIL) TABLET [ANI PHARMACEUTICALS, INC.] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2025

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[RMED38003444] An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release.

Original source / bibliographic reference

Authors: Fleisher-Berkovich S, Battaglia V, Baratta F, Brusa P, Ventura Y, Sharon N, Dahan A, Collino M, Ben-Shabat S.

Year: 2023

Source type: Original publication; see finding for study type

DOI: 10.3390/ijms242216254

PMID: 38003444

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility